ALT — Altimmune Cashflow Statement
0.000.00%
Last trade - 00:00
- $489.89m
- $292.07m
- $0.43m
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -20.5 | -49 | -97.1 | -84.7 | -88.4 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 8.77 | 18.8 | 18.6 | 8.02 | 20.4 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.82 | -4.51 | -0.251 | 14.1 | -8.27 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -9.6 | -34.3 | -78.2 | -62.6 | -75.8 |
Capital Expenditures | -0.029 | -0.342 | -12.3 | -0.126 | -0.047 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -28.3 | -71.9 | 99.8 | -73.3 | 13.8 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -28.3 | -72.2 | 87.5 | -73.4 | 13.7 |
Financing Cash Flow Items | — | 0 | -0.119 | 0 | -0.824 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 12.5 | 213 | 65.1 | 56.8 | 86.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -25.4 | 107 | 74.4 | -79.2 | 24 |